Your SlideShare is downloading. ×
abcam - NOAH13 London
abcam - NOAH13 London
abcam - NOAH13 London
abcam - NOAH13 London
abcam - NOAH13 London
abcam - NOAH13 London
abcam - NOAH13 London
abcam - NOAH13 London
abcam - NOAH13 London
abcam - NOAH13 London
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

abcam - NOAH13 London

264

Published on

The Internet of Antibodies - Presentation by Jonathan Milner, Co-Founder & CEO of abcam at the NOAH 2013 Conference in London, Old Billingsgate on the 13th of November 2013.

The Internet of Antibodies - Presentation by Jonathan Milner, Co-Founder & CEO of abcam at the NOAH 2013 Conference in London, Old Billingsgate on the 13th of November 2013.

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
264
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. The Internet of Antibodies Jonathan Milner Founder & CEO of Abcam plc
  • 2. Introduction • Jonathan Milner, Founder & CEO • Former lifescience research scientist – studied breast cancer genes at Cambridge university • Very exciting time at the start of a golden age of biological research • Unable to buy the reagents needed to conduct gene studies • Founded Abcam in 1998 to sell these reagents – antibodies – from an online catalogue • Vision to create the largest catalogue of the best antibodies in the world • Acquisitions have broadened Abcam into a world leader in protein research tools 2
  • 3. Abcam in numbers Sales Pre-tax profits Market cap £122m £46.5m c£1bn (year to 30 June 2013) (year to 30 June 2013) (£58m at IPO in 2005) Web pages in Google Publications referencing Abcam products in 2012 Delivering to index 1.75m (source: Google Search) c24k (source: Google Scholar) Number of products c125,000 >100 countries worldwide 3
  • 4. What we do • Manufacture, source and sell protein research tools including antibodies – Tens of thousands of proteins interact in millions of ways • Antibodies enable research – picks and shovels for studying proteins at a cellular level • Used in scientific breakthroughs leading to new treatments for diseases such as cancer • International customer base – academia to global pharma • The US is Abcam’s largest market – huge US investment in lab bench research • Competitors include Life Technologies, Merck Millipore, Santa Cruz Biotechnology 4
  • 5. The internet of antibodies • Historically, laboratory reagents were sold from paper catalogues – Limited quantity and timeliness of information , minimal customer interaction • The internet meant product information could be hosted online • Potential for huge quantities of relevant, continually updated information • This information is open source and unique to Abcam products • Dynamic relationship created with online community of scientists • Products manufactured in-house or sourced from third parties and branded Abcam 5
  • 6. The information flywheel • The quicker product information is added, the faster sales grow • More sales lead to an increased rate of information addition • This leads to improved sales and better pricing • Ultimately this makes the business highly defensible 6
  • 7. Catalogue growth by product over time 130,000 Number of products on the Abcam calalogue over time 120,000 110,000 100,000 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 H1 H2 2001/02 H1 H2 2002/03 H1 H2 2003/04 OEM Primary Antibodies H1 H2 2004/05 H1 H2 2005/06 OEM Other Products H1 H2 2006/07 H1 H2 2007/08 H1 H2 2008/09 Abcam Primary Antibodies H1 H2 2009/10 H1 H2 2010/11 H1 H2 2011/12 Abcam Other Products H1 H2 2012/13
  • 8. Sales momentum in the catalogue including unaudited pre-acquisition revenues of Epitomics (reagents) and Ascent 60000 Revenue £k calculated at fixed exchange rates 50000 40000 30000 20000 10000 0 H1 H2 2002 / 03 H1 H2 2003 / 04 H1 H2 2004 / 05 H1 H2 2005 / 06 H1 H2 2006 / 07 H1 H2 2007 / 08 H1 H2 2008 / 09 H1 H2 2009 / 10 H1 H2 2010 / 11 H1 H2 2011/12 H1 H2 2012/13 Added pre 2002 / 03 Added in 2002 / 03 Added in 2003 / 04 Added in 2004 / 05 Added in 2005 / 06 Added in 2006 / 07 Added in 2007 / 08 Added in 2008 / 09 Added in 2009 / 10 Added in 2010 / 11 Added in 2011 / 12 Added in 2012 / 13
  • 9. Continual improvement • Our website is an ever more important tool for our business • IT team continues to focus on uptime and responsiveness – 99.99% uptime on our website – Response time of < 2 seconds for searches • Improving accessibility and functionality of the front-end website • Re-engineering core systems to enhance scalability • Customer surveys, customer focus groups and randomly sampling web visitors 9
  • 10. How big can it get? • Business model designed for scalability • High growth market fuelled by scientific advances • Recent acquisition of a US company, Epitomics, with exciting new technology • Vision to create the world’s leading lifescience reagents company www.abcam.com 10

×